Neuroimaging in Parkinson's Disease

被引：56

作者：

Brooks D.J. ^{[1
]}

机构：

[1] Medical Research Council Clinical Sciences Center, Division of Neuroscience, Faculty of Medicine

来源：

NeuroRX | 2004年 / 1卷 / 2期

关键词：

dopamine; neuroprotection; Parkinson's disease; Positron emission tomography; progression; SPECT;

D O I：

10.1602/neurorx.1.2.243

中图分类号：

学科分类号：

摘要：

In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：243 / 254

页数：11

共 94 条

[11]

McKeith I., Galasko D., Kosaka K., Et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology, 47, pp. 1113-1124, (1996)

[12]

Morrish P., Sawle G., Brooks D., Clinical and [18F]dopa PET findings in early Parkinson's disease, J Neurol Neurosurg Psychiatry, 59, pp. 597-600, (1995)

[13]

Rakshi J., Uema T., Ito K., Et al., Frontal, striatal, and midbrain dopaminergic function in early and advanced Parkinson's disease: a 3D 18F-dopa PET study, Brain, 122, pp. 1637-1650, (1999)

[14]

Brooks D., Ibanez V., Sawle G., Et al., Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy, Ann Neurol, 28, pp. 547-555, (1990)

[15]

Leenders K., Salmon E., Tyrrell P., Et al., The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease, Arch Neurol, 47, pp. 1290-1298, (1990)

[16]

Bernheimer H., Birkmayer W., Hornykiewicz O., Et al., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations, J Neurol Sci, 20, pp. 415-455, (1973)

[17]

Lindvall O., Bjorklund A., Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway, Brain Res, 172, pp. 169-173, (1979)

[18]

Whone A., Moore R., Piccini P., Brooks D., Plasticity in the nigropallidal pathway in Parkinson's disease: an 18F-dopa PET study, Ann Neurol, 53, pp. 206-213, (2003)

[19]

Frost J., Rosier A., Reich S., Et al., Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease, Ann Neurol, 34, pp. 423-431, (1993)

[20]

Rinne J., Bergman J., Ruotinnen H., Et al., Striatal uptake of a novel PET ligand, [18F]b-CFT, is reduced in early Parkinson's disease, Synapse, 31, pp. 119-124, (1999)

← 1 2 3 4 5 6 7 8 9 10 →